Marekani - Kiingereza - NLM (National Library of Medicine)

bluebay shandong co.,ltd - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) -

Marekani - Kiingereza - NLM (National Library of Medicine)

ax pharmaceutical corp - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) -

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 400 mg in 1 ml - adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. - known or suspected pregnancy or as a diagnostic test for pregnancy - undiagnosed vaginal bleeding - known or suspected malignancy of breast - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease - liver dysfunction or disease - known sensitivity to depo-provera (medroxyprogesterone acetate or any of its other ingredients).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium stearate; lactose monohydrate; sucrose; purified talc; liquid paraffin; maize starch - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate; maize starch - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: calcium stearate; liquid paraffin; sucrose; lactose monohydrate; indigo carmine; maize starch; purified talc - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: purified talc; sucrose; lactose monohydrate; maize starch; calcium stearate; liquid paraffin - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; calcium stearate; liquid paraffin; sucrose; purified talc; maize starch - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.